Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Portfolio Pulse from Benzinga Insights
Immunocore Holdings (NASDAQ:IMCR) has received diverse analyst ratings, with 8 analysts offering perspectives ranging from bullish to bearish in the last three months. The average 12-month price target for IMCR has been raised to $81.00, an 11.57% increase from the previous target of $72.60. Analysts from firms including Needham, JP Morgan, HC Wainwright & Co., Mizuho, Oppenheimer, and Canaccord Genuity have updated their ratings and price targets, reflecting a generally positive outlook on the stock. Immunocore's financial performance shows significant revenue growth but challenges in net margin, ROE, and ROA, with a sound debt management profile.
April 11, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunocore Holdings has seen a positive shift in analyst ratings, with an increased average price target of $81.00, indicating a bullish outlook from financial experts.
The increase in the average price target to $81.00, up from $72.60, reflects analysts' growing confidence in Immunocore's potential, likely due to its significant revenue growth and innovative TCR bispecific immunotherapies. Despite some financial challenges, the overall bullish sentiment from analysts suggests a positive short-term impact on IMCR's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100